Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2013

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This study will provide chronic hepatitis C patients with low platelets (less than 75x10\^9/L) the opportunity to undergo treatment and possible cure of their virus. The main hepatitis C drugs will be administered as standard of care, with the addition of the study drug eltrombopag.

The investigators hypothesize that providing eltrombopag to chronic hepatitis C patients with low platelets (less than 75x10\^9/L) will permit the initiation and completion of antiviral triple therapy with boceprevir, ribavirin, and pegylated-interferon.
Epistemonikos ID: 759a44996f36b3f20780e37d6ba9d7d4ab08b672
First added on: May 11, 2024